AURA Company Profile and Key Details

AURA has shown mixed momentum, losing -1.97% over the past week and -12.35% over the past quarter, though year-to-date performance is down -8.81%. Short-term trend indicators are mixed aligned (SMA20 6.87%, SMA50 7.75%, SMA200 -1.41%). The stock’s 14-day RSI is 59.46 (neutral), while the ATR of 0.37 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -22.64% below its high and over 37.63% above its low. Average 10-day trading volume of 441.25 thousand shares is below the 3-month average of 492.75 thousand, indicating normal recent market interest.

Aura Biosciences, Inc. has 63.50 million shares outstanding. The public float is 36.46 million shares, elevated short interest at 4.49% of float. This equals 2.51 million shares. The short ratio is 9.85 days. Institutional investors hold 86.07% of the float. Insiders own 1.87%. de los Pinos Elisabet holds 409.82 thousand shares, Hopkins Janet Jill has 232.28 thousand shares and Kilroy Conor has 217.84 thousand shares. Over the past six months, insider transactions show net selling. They sold 7.06 million shares across 9 transactions.

Aura Biosciences, Inc. generated EPS of -$1.93 over the past year. Five-year average earnings growth is -11.09%. Wall Street analysts project EPS growth of -0.63% annually over the next five years. The latest quarter delivered EPS of -$0.50. The next quarter is forecast at -$0.43. Next year's EPS is expected at $4.03. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $24.00 to $13.00. The high target offers 220.0% upside. The low target suggests 73.33% downside. The mean target is $20.25. This offers 170.0% upside. Aura Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended May 11, 2026, missed forecasts by 25.0%. The prior quarter beat by -13.95%. Over the last six quarters, Apple has recorded several small beats. These include 20.93% in March 24, 2025.

Aura Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.70. This means the shares are trading above this model’s fair value.

Aura Biosciences, Inc. (NASDAQ:AURA) closed at $7.47 USD, losing -$0.03 (-0.38%) from the previous close of $7.50. The stock is currently mid-range between its 52-week high and low $4.73 and $9.54. With a market capitalization of about $479.65 million, Aura Biosciences, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.37). Key stats such as the average daily volume over the past year has been around 476.67 thousand shares, volume is running light vs its 52-week average. Headquartered in Boston, MA, Aura Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Elisabet de los Pinos, the company employs approximately 106 people and listed since October 29, 2021. Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer.

Our AI price prediction model suggests that Aura Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.27%, with price expected at $7.48 by June 11, 2026, within a range of $7.04 to $7.93 3-Month Outlook: Projected fall of -26.93%, reaching $5.48 by August 26, 2026, with a range of $4.79 to $5.95. 1-Year Outlook: Projected gain of 215.2%, with price at $23.64 by May 28, 2027, within a range of $17.25 to $32.22.

Aura Biosciences, Inc. (NASDAQ:AURA) shares are flat -8.81% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Aura Biosciences, Inc. trading at a premium to the broader market with a P/E of -4.57. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $23.31, suggesting 210.8% upside. Our AI forecast model points to short-term weakness (-0.27% over two weeks), a medium-term fall (-26.93% over three months), and a longer-term gain (215.2% over one year), with expected trading ranges indicating moderate volatility.

Aura Biosciences, Inc. trades at a P/E ratio of -4.57, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.79 trading at moderately above to book value. The P/FCF stands at -5.34, also above market averages.